Caps drug costs, expands price negotiation, and limits out-of-pocket spending for privately insured Americans.
This bill would help Americans with private health insurance by setting new limits on how much they pay out-of-pocket for prescription drugs, including a $35 cap on insulin costs. It would also expand the government's ability to negotiate lower prices for more drugs and apply Medicare's drug inflation rebates to the commercial market. These changes aim to make prescription drugs more affordable for many families.
Today, people with private health insurance often face high deductibles and unlimited out-of-pocket costs for all health services and prescription drugs. Drug manufacturers are also not required to pay inflation rebates for commercially sold drugs. This bill would set overall annual out-of-pocket limits for all health services, including prescription drugs, and also a separate annual out-of-pocket limit specifically for prescription drugs. It would cap insulin costs at $35 per month and require manufacturers to pay rebates if their drug prices rise faster than inflation for privately insured individuals.
HR 6166 · 119th Congress · November 20, 2025 · AI Summary by gemini-2.5-flash · 8/10
Sign in to see your representatives' phone numbers
6 filings mentioned this bill
Amounts reflect total quarterly lobbying spend reported to the Senate, not bill-specific spending. Source: Senate LDA filings.